TMEM26: A Transmembrane Protein Target for Drug Development and Disease Treatment

Target Name: TMEM26

NCBI ID: G219623

TMEM26

TMEM26: A Transmembrane Protein Target for Drug Development and Disease Treatment

TMEM26, a member of the transmembrane protein (TMEM) family, is a unique protein that has caught the attention of researchers due to its unique structure, localization, and functions. TMEM26 is expressed in various tissues and cell types in the human body, including the brain, pancreas, and heart, making it an attractive candidate for drug targeting. Additionally, its unique expression pattern in cancer cells has led to its potential as a biomarker for disease diagnosis and treatment.

Structure and Localization

TMEM26 is a 21-kDa protein that consists of 15 transmembrane浼?-helices and a cytoplasmic tail. Its transmembrane regions are characterized by an N-terminal region that contains a putative intracellular loop, a catalytic domain, and a C-terminal region that contains a putative glycophorin domain and a carcass domain. TMEM26 is predominantly expressed in the brain, pancreas, and heart, with lower levels observed in other tissues, such as the lungs and gastrointestinal tract.

Function

TMEM26 functions as a transmembrane protein that plays a role in various physiological processes, including cell signaling, protein transport, and modulation of cell adhesion. TMEM26 is involved in the regulation of ion channels, such as Na+ and K+ channels, which are critical for the rapid and delayed responses of neurons and other cell types. Additionally, TMEM26 is involved in the regulation of protein transport, specifically in the transport of nucleotides out of the cell.

Drug Targeting

The unique structure and localization of TMEM26 make it an attractive drug target. Drugs that target TMEM26 have the potential to modulate various cellular processes and disrupt its functions, leading to therapeutic benefits. For example, inhibition of TMEM26 has been shown to reduce the migration and invasion of cancer cells, leading to a potential therapeutic approach for cancer treatment. Additionally, TMEM26 has been shown to play a role in the regulation of pain perception, making it a potential target for pain management.

Biomarker

The expression pattern of TMEM26 in various tissues and cancer types has led to its potential as a biomarker for disease diagnosis and treatment. For example, high expression of TMEM26 has been shown to be associated with poor prognosis in pancreatic ductal adenocarcinoma, a type of pancreatic cancer. Similarly, high expression of TMEM26 has been shown to be associated with the development of colorectal cancer, a type of cancer that is a leading cause of cancer-related death.

Conclusion

TMEM26 is a unique transmembrane protein that has caught the attention of researchers due to its unique structure and localization. Its functions in cell signaling, protein transport, and modulation of cell adhesion make it an attractive candidate for drug targeting. Additionally, its unique expression pattern in various tissues and cancer types has led to its potential as a biomarker for disease diagnosis and treatment. As research continues to advance, TMEM26 is sure to become a valuable tool for the development of new therapeutic approaches for a variety of diseases.

Protein Name: Transmembrane Protein 26

The "TMEM26 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about TMEM26 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets